Opsoclonus is a striking neurological sign in which the eyes make rapid, involuntary, chaotic movements in multiple directions at once, without the normal pauses that usually separate one eye movement from the next. It can appear suddenly in an otherwise healthy child or adult, and its presence almost always signals something worth investigating, because in roughly half of affected children it is the first visible clue to a hidden tumor called neuroblastoma. In adults the trigger is more varied, ranging from lung and breast cancers to viral infections and even scorpion stings, but the underlying theme is consistent: something has gone wrong with the brain circuits that keep the eyes still.
What Opsoclonus Looks Like
The hallmark of opsoclonus is back-to-back saccades, the fast flicking movements the eyes normally use to jump from one target to another. In a healthy person, each saccade is followed by a brief pause before the next one fires. In opsoclonus, those pauses disappear. The eyes oscillate around the center of gaze continuously, and the movements happen in all planes: horizontal, vertical, and rotational. The result looks like the eyes are dancing or shaking unpredictably, sometimes described by clinicians as “saccadomania.”1PubMed. Opsoclonus and ocular flutter: evaluation and management
A related but narrower phenomenon is ocular flutter, where the same back-to-back saccades occur but only in the horizontal plane. Flutter and opsoclonus are often grouped together because they share a mechanism and frequently appear in the same patient at different moments, but the distinction matters for documentation: true opsoclonus involves multidirectional movement, while flutter stays side to side.2PubMed. Opsoclonus and ocular flutter: evaluation and management Some patients also experience opsoclonus only in certain gaze positions. One case report described a man with mild traumatic brain injury who had small-amplitude opsoclonus only when looking to the left, alongside flutter during convergence.3PubMed. Eye position-dependent opsoclonus in mild traumatic brain injury
Opsoclonus rarely appears in isolation. Most people who develop it also have myoclonus (sudden brief muscle jerks), ataxia (unsteady balance and coordination), and sometimes behavioral changes like irritability, sleep disruption, or intense fear. When the triad of opsoclonus, myoclonus, and ataxia appears together it is called opsoclonus-myoclonus syndrome, or OMS. In children, the full presentation can be alarming: a toddler who was walking normally may become unable to stand, with trembling limbs and eyes that dart uncontrollably.
The Brain Circuitry Behind It
The leading theory points to a group of neurons in the brainstem called omnipause neurons. These cells normally fire continuously to suppress saccades when the eyes should be still, and they go silent only briefly each time the brain commands an intentional eye movement. When omnipause neurons stop doing their job, saccades fire unchecked, producing the chaotic oscillations that define opsoclonus.
Early researchers examined the brainstems of patients with opsoclonus caused by lung cancer and found that the omnipause neurons looked structurally normal under the microscope. The neurons were present and appeared intact, which suggested that the problem was not cell death but rather a functional disturbance, likely a disruption in the chemical signals or neurotransmitters those neurons depend on.4Oxford Academic (Brain). Omnipause neurons in two cases of opsoclonus associated with oat cell carcinoma of the lung This insight has shaped the modern understanding of OMS as primarily an immune-mediated disorder: antibodies or immune cells interfere with how these neurons communicate, rather than destroying them outright.
The Neuroblastoma Connection in Children
In children, about half of OMS cases are linked to neuroblastoma, a cancer that arises from immature nerve tissue and typically appears as a small mass near the spine or in the abdomen.5PubMed Central. Neuroblastoma presenting as opsoclonus-myoclonus: A series of six cases and review of literature The connection runs both directions but at very different rates: while half of children with OMS turn out to have a neuroblastoma, only about two to three percent of children with neuroblastoma develop OMS.
There is a peculiar silver lining here. The neuroblastomas found in children with OMS tend to be small, early-stage tumors without the genetic markers (like MYCN amplification) that signal aggressive disease. Historically, the association between the two conditions was first described as early as 1927, though it took until 1968 for researchers to formally recognize the connection.6PubMed Central. The association between neuroblastoma and opsoclonus-myoclonus syndrome: a historical review The tumor itself is usually curable. The neurological syndrome, paradoxically, often proves harder to control than the cancer.
In a case series of six children with neuroblastoma-associated OMS, the neurological symptoms appeared before the tumor was discovered in every single case.7PubMed Central. Neuroblastoma presenting as opsoclonus-myoclonus: A series of six cases and review of literature This means opsoclonus often serves as the alarm bell that sends doctors looking for a tumor they otherwise would not have found yet. Any child who develops unexplained opsoclonus gets a thorough search for neuroblastoma as part of the standard workup.
Cancer-Related Opsoclonus in Adults
In adults, small-cell lung cancer is the tumor most frequently linked to OMS.8PubMed Central. Paraneoplastic Opsoclonus-Myoclonus Syndrome as a Rare Presentation of Small-Cell Lung Cancer A study of adult OMS patients found that among those with cancer, small-cell lung cancer accounted for the largest share, followed by breast cancer, with occasional cases linked to gastric and kidney tumors.9Brain. Clinical outcome in adult onset idiopathic or paraneoplastic opsoclonus–myoclonus Breast cancer in particular has a well-documented connection through specific antibodies.
The antibody called anti-Ri was originally identified in women with paraneoplastic ataxia and opsoclonus, most of whom had breast or other gynecological cancers. Anti-Ri targets specific neuronal proteins and, when found in a patient’s blood or spinal fluid, strongly suggests an underlying malignancy.10PubMed. Anti-Ri: an antibody associated with paraneoplastic opsoclonus and breast cancer More recently, a case of breast cancer presenting with ocular flutter was confirmed through anti-Ri antibody testing, reinforcing that these antibodies remain a practical diagnostic marker decades after their discovery.11PubMed Central. Anti-Ri Paraneoplastic Neurological Syndrome Presenting with Ocular Flutter in a Patient with Breast Cancer
In children with neuroblastoma-related OMS, the antibody picture is different. Rather than anti-Ri, researchers have found that sera from these children contain antibodies that bind to cerebellar Purkinje cells and to a 210-kilodalton neurofilament protein. Control subjects showed no such pattern, suggesting a distinctive autoimmune signature specific to childhood OMS.12PubMed. Serum autoantibodies in childhood opsoclonus-myoclonus syndrome: an analysis of antigenic targets in neural tissues
Infections, Drugs, and Other Triggers
Not all opsoclonus is cancer-related. Viral infections can trigger the same syndrome, presumably by provoking a misdirected immune attack on the brain. COVID-19 brought renewed attention to this possibility: a case series described seven patients who developed OMS as a post-infectious complication of SARS-CoV-2 infection.13PubMed Central. Opsoclonus-myoclonus syndrome, a post-infectious neurologic complication of COVID-19: case series and review of literature Other infections historically linked to OMS include Epstein-Barr virus, West Nile virus, and various enteroviral infections, though the evidence for each is mostly limited to individual case reports.
Drugs and toxins can also cause opsoclonus through direct effects on brainstem neurotransmitter systems. A systematic review found 158 reported cases of toxic or drug-induced opsoclonus. The single largest category, accounting for nearly three-quarters of all cases, was bark scorpion poisoning. Chlordecone intoxication (an industrial pesticide exposure) accounted for about nine percent. The remaining cases involved a scattered list of pharmaceuticals and chemicals affecting various neurotransmitter pathways, including those involving acetylcholine, glutamate, GABA, and dopamine.14PubMed Central. Drug- and Toxin-Induced Opsoclonus – a Systematized Review, including a Case Report on Amantadine-Induced Opsoclonus in Multiple System Atrophy Even the anti-seizure drug lamotrigine has been reported to produce opsoclonus at toxic levels.15PubMed. Opsoclonus myoclonus induced by lamotrigine toxicity
There is also a sizable group of patients, both children and adults, in whom no tumor, infection, or toxic exposure can be found. These idiopathic cases are treated essentially the same as paraneoplastic ones, because the immune-mediated mechanism appears to be the same regardless of what originally triggered it.
Finding the Cause
Once opsoclonus is recognized, the diagnostic workup branches in two directions: looking for a hidden tumor and testing for antibodies that might point to one.
In children, the search for neuroblastoma traditionally begins with urine catecholamine metabolites and imaging. A standard scintigraphy scan (MIBG scan) is often the first-line imaging study, but it can be inconclusive. When it is, whole-body MRI has shown value as an alternative in the early diagnostic phase.16PubMed Central. Diagnostic value of whole-body MRI in Opsoclonus-myoclonus syndrome: a clinical case series (3 case reports) A newer approach uses a specialized PET/CT scan targeting somatostatin receptors, which neuroblastoma cells tend to express. In one study of 38 children with OMS, this type of PET/CT correctly identified all 17 neuroblastic tumors and had an overall accuracy above 97 percent, with no tumors missed among those scanned.17PubMed. Diagnostic values of (68)Ga-labelled DOTANOC PET/CT imaging in pediatric patients presenting with paraneoplastic opsoclonus myoclonus ataxia syndrome
In adults, the antibody panel typically includes tests for anti-Ri, anti-Hu, and other paraneoplastic antibodies. A positive anti-Ri result in a woman with OMS should prompt a thorough search for breast cancer.18PubMed. Anti-Ri: an antibody associated with paraneoplastic opsoclonus and breast cancer CT scans of the chest are standard when small-cell lung cancer is suspected. Even when initial imaging is negative, many clinicians recommend repeated surveillance, because the tumors associated with OMS are often small enough to evade detection on a first scan.
Treatment
Because OMS is driven by the immune system attacking brain circuits, treatment centers on suppressing that immune response. If a tumor is present, removing or treating it is always part of the plan, but tumor treatment alone rarely resolves the neurological symptoms. Immunotherapy is almost always needed alongside.
In children, the first-line agents have historically been corticotropin (ACTH), corticosteroids like dexamethasone, and intravenous immunoglobulin (IVIG). A study of 105 pediatric cases found that ACTH, prednisone, and IVIG were used with roughly equal frequency, but ACTH was associated with the best early response.19PubMed. Neuroepidemiologic trends in 105 US cases of pediatric opsoclonus-myoclonus syndrome However, single-agent therapy often falls short. A controlled study of 74 children showed that motor symptom severity improved about 65 percent overall across all treatment groups, but combinations of immunotherapies consistently outperformed corticotropin alone.20PubMed. Active comparator-controlled, rater-blinded study of corticotropin-based immunotherapies for opsoclonus-myoclonus syndrome
Rituximab, an antibody that depletes B cells, has become a key addition. In one study, 81 percent of children with OMS had lower motor severity scores after rituximab, with a 44 percent reduction in the average total severity score. Opsoclonus, ataxia, and behavioral symptoms like rage all improved. B-cell counts in the spinal fluid dropped to undetectable levels in several children, and most patients on ACTH were able to reduce their dose without relapsing.21PubMed. Rituximab (anti-CD20) adjunctive therapy for opsoclonus-myoclonus syndrome Individual case reports echo this: one child who worsened on dexamethasone alone achieved remission within twelve months after rituximab was added, with cerebrospinal fluid B-cell percentage falling from about 11 percent to near zero.22Brain and Development Case Reports. Pediatric opsoclonus myoclonus syndrome with improvement of symptoms and decrease in cerebrospinal fluid B cell percentage after rituxmab administration: Case report
The current thinking favors aggressive multimodal immunotherapy from the start. A recent pediatric study concluded that combining intravenous dexamethasone, IVIG, and rituximab can reduce both relapses and permanent neurological damage compared with less aggressive approaches.23PubMed Central. The utilization of the multimodal immunotherapy for the opsoclonus-myoclonus syndrome can reduce relapses and permanent neurological sequelae
The Relapse Problem
One of the most frustrating aspects of OMS is its tendency to come back. Even children who respond well to initial treatment frequently relapse when medications are tapered. In a pilot study of mycophenolate mofetil, a steroid-sparing immunosuppressant, researchers found that 73 percent of children eventually relapsed despite maintaining therapeutic drug levels, even though ACTH doses had been reduced by about 64 percent. Interestingly, prior treatment with rituximab appeared to prevent a spike in B cells during relapse, suggesting the two drugs complement each other even though neither alone prevents relapses completely.24PubMed. Insights on chronic-relapsing opsoclonus-myoclonus from a pilot study of mycophenolate mofetil
The relapse-prone nature of OMS means many children remain on immunotherapy for years. Weaning off treatment is typically a slow, cautious process, and some patients need repeated courses of rituximab or long-term low-dose steroids to stay stable. Each relapse carries the risk of additional neurological injury, which is why early aggressive treatment has gained favor.
Long-Term Neurological Outcomes
Even when the opsoclonus itself resolves, many patients are left with lasting neurological effects. Roughly 70 percent of patients experience ongoing neurological, cognitive, or behavioral difficulties.25Arquivos Brasileiros de Oftalmologia. Adult-onset idiopathic opsoclonus-myoclonus syndrome In adults, these sequelae tend to be relatively mild, often limited to residual gait unsteadiness and some slurring of speech. In children, the consequences are more varied and can be more severe.
A Children’s Oncology Group report that tracked cognitive functioning over time in children with neuroblastoma-related OMS found that cognitive scores remained stable over the first two years of follow-up but did not show clear recovery. There was no statistically significant change in either direction, meaning the cognitive plateau set by the disease largely persisted.26PubMed Central. Late Cognitive and Adaptive Outcomes of Patients with Neuroblastoma-Associated Opsoclonus-Myoclonus-Ataxia-Syndrome: A Report from the Children’s Oncology Group Another study found that girls and children with residual tumor tissue after surgery were more likely to have motor delays, while children whose neuroblastoma was located outside the adrenal gland were more prone to language impairment.27PubMed Central. Long-term neurological outcomes of children with neuroblastoma with opsoclonus-myoclonus syndrome
There is emerging evidence that how aggressively the tumor itself is treated may influence neurological outcomes. One study from a resource-limited setting found that children who received chemotherapy for their neuroblastoma had significantly better neurological outcomes than those who did not, and that chemotherapy was the only variable that independently predicted a favorable result.28Journal of Pediatric Hematology/Oncology. Neuroblastoma With Opsoclonus-Myoclonus-Ataxia Syndrome: Role of Chemotherapy in the Management: Experience From a Tertiary Care Center in a Resource-limited Setting This is somewhat counterintuitive, because the neuroblastomas associated with OMS are typically low-stage tumors that would not normally require chemotherapy based on cancer staging alone. It raises the possibility that reducing tumor burden with chemotherapy also reduces the ongoing immune stimulus driving brain injury.
What Brain Imaging Shows
Standard MRI scans of the brain in OMS patients usually look normal, which can be frustrating for clinicians trying to understand why the patient’s eyes are dancing and their balance is wrecked. Functional imaging studies, however, reveal a different story. Children with OMS show abnormal connectivity patterns between brain regions: the motor cortex has weaker-than-normal connections to the cerebellum, while the visual and parietal regions show unusually strong cerebellar connectivity. There is also an extensive visual network linking the cerebellum to the basal ganglia that does not appear in healthy children at all.29PubMed. Altered functional brain connectivity in children and young people with opsoclonus-myoclonus syndrome
Longitudinal imaging of an adult patient with paraneoplastic OMS added metabolic detail. During the acute phase, PET scanning showed dramatically increased metabolism around the deep cerebellar nuclei, particularly the fastigial nucleus, alongside reduced metabolism in the visual cortex. As the opsoclonus resolved over the following year, these metabolic abnormalities normalized. Functional connectivity between oculomotor and visual brain structures was also elevated during the acute phase and then decreased as symptoms improved.30PubMed. Longitudinal multi-modal neuroimaging in opsoclonus-myoclonus syndrome These findings align with the omnipause neuron theory: the deep cerebellar nuclei interact closely with the brainstem circuits that normally keep saccades in check, and overactivity there could contribute to the disinhibited eye movements.
Subtle Signs That Linger After Recovery
Even children who appear clinically recovered from OMS may retain subtle abnormalities in how their eyes move. A study tracking saccade behavior during a natural viewing task found that children recovering from OMS took longer to initiate saccades after a visual scene change compared with healthy children. Their fixation patterns were also different, suggesting lingering changes in the midbrain circuits that coordinate eye movements and attention.31PubMed Central. Saccade and pupil changes in children recovering from opsoclonus-myoclonus ataxia syndrome reveal midbrain alterations in oculomotor circuits These differences are too small for parents or teachers to notice in daily life, but they point to measurable traces of the disease in brain function long after the dramatic symptoms have faded. Whether these subclinical changes contribute to the learning difficulties and attention problems reported in many OMS survivors is not yet clear, but the correlation is hard to ignore.